Daniel Petrylak, MD, of the Yale School of Medicine, New Haven, CT, discusses a phase 1 study of PSMA ADC, (antibody-drug conjugate) targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
- PSMA ADC for prostate cancer ( Download)
- PSMA ADC in prostate cancer: Phase I results ( Download)
- Dr. Nicholas Vogelzang Discusses PSMA ADC in Prostate Cancer ( Download)
- Dr. Petrylak on PSMA ADC for Patients with mCRPC ( Download)
- Dr. Petrylak on a Phase II Trial of PSMA ADC in Taxane-Treated mCRPC ( Download)
- Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC ( Download)
- What role will ADCs play in the prostate cancer treatment landscape ( Download)
- What are the latest in ADCs for prostate and bladder cancer ( Download)
- PSMA - Targeted T Cells for the Treatment of Prostate Cancer ( Download)
- Prostate Cancer, PSMA PET and Functional Imaging ( Download)
- Dr. Petrylak Discusses PSMA-Directed Therapies in Prostate Cancer ( Download)
- PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022 ( Download)
- Prostate Imaging: MRIs & PSMA | Steven Raman, MD & Mark Moyad, MD, MPH | #PCRI #ProstateCancer ( Download)
- Next Gen Imaging for Adv Prostate Cancer - 2021 Issue ( Download)
- Dr. Tagawa Discusses Agents Targeted Against PSMA ( Download)
